Polyionic Compounds Selectively Alter Availability of CD4 Receptors for HIV Coat Protein rgp 120

  • A. Aszalos
  • P. S. Pine
  • J. Weaver
Conference paper


We studied the ability of several polyionic compounds, previously shown to have anti-HIV activity in vitro, to block binding of anti-CD4 and recombinant HIV gp120 to the CD4 receptor on human lymphocytes. We found that Evans Blue and aurin tricarboxylic acid (ATA) could completely inhibit binding of anti-CD4 (Leu 3a) and rgp120 and have selectivity for the CD4 receptor. A number of other compounds including dextran sulfate and heparin had no effect on binding of rgp120 and were shown to be nonspecific for inhibition of binding of monoclonal antibodies to different T-cell receptors. Studies using a number of membrane-active drugs showed that changes in membrane potential or ion fluxes were not involved in the inhibition of binding of rgp 120 by Evans Blue or aurin tricarboxylic acid. Using our developed flow cytometric method we could detect novel compounds which can prevent binding of rgp120 specifically and have good anti-HIV activity.

We have also found that ATA prevents the binding of interferon-α to its receptor in a dose dependent manner (12–50 µM range). Membrane potential shift, associated with the binding of interferon-α to its receptor, was also blocked by ATA in a dose dependent fashion. Several other agents, able to prevent the binding of rgp120 to the CD4 molecule, did not block the binding of interferon-α to its receptor. Our results indicate that potential anti-AIDS drugs should be screened for such undesired side effects.


Evans Blue Dextran Sulfate Evans Blue Dextran Sulfate Daudi Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lifson JD, Hwang KM, Nara PL, Fraser B, Padgett M, Dunlop NM and Eiden LE, Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 241: 712–716, 1988.PubMedCrossRefGoogle Scholar
  2. 2.
    Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE and Capon D, Blocking of HIV-1 infectivity by a soluble secreted form of the CD4 antigen. Science 238: 1704–1707, 1987.PubMedCrossRefGoogle Scholar
  3. 3.
    Baba M, Pauwels R, Balzarini J, Arnout J and Desmyter J, Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 85: 6132–6136, 1988.CrossRefGoogle Scholar
  4. 4.
    Schols D, Baba M, Pauwels R and De Clercq E, Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells. J. Acq. 1mm. Def. Synd. 2: 10–15, 1989.Google Scholar
  5. 5.
    Mizumoto K, Sugawara I, Ito W, Kodama T, Hayami M and Mori S, Sulfated homopolysaccharides with immunomodulating activities are more potent anti-HTLV-IH agents than sulfated heteropolysaccharides, Japan J. Exp. Med. 58: 145–151, 1988.Google Scholar
  6. 6.
    Schols D, Baba M, Pauwels R, Desmyter J and De Clercq E, Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 receptor. Proc. Natl. Acad. Sci. USA 86: 3322–3326, 1989.PubMedCrossRefGoogle Scholar
  7. 7.
    Cushman M, Kanamathareddy S, De Clercq E, Schols D, Goldman ME and Bowen JA, Synthesis and anti-HIV activities of low molecural weight aurintricarboxylic acid fragments and related compounds. J. Med. Chem. 34: 337–342, 1991.PubMedCrossRefGoogle Scholar
  8. 8.
    Balzarini J, Mitsuya H, De Clercq E and Broder S, Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem. Biophys. Res. Commun. 136: 64–71, 1986.PubMedCrossRefGoogle Scholar
  9. 9.
    Balzarini J, Mitsuya H, De Clercq E and Broder S, Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotrophic virus (HTLV-IH)/lymphadenopathy-associated virus (LAV). Int. J. Cancer 37: 451–457, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Stall F and Broder S, Dextran sulfate suppression of viruses in the HIV family: Inhibition of virion binding to CD4 + cells. Science 240: 646–649, 1988.PubMedCrossRefGoogle Scholar
  11. 11.
    Lederman S, Gullck R and Chess L, Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (GP120) of HIV. J. Immunol. 143: 1149–1154, 1989.PubMedGoogle Scholar
  12. 12.
    Weaver JL, Gergeley P, Pine PS, Patzer E and Aszalos A, Polyionic compounds selectively alter availability of CD4 receptors for HIV coat protein rgp120. AIDS Res. Human Retrovir. 6: 1125–1130, 1990.CrossRefGoogle Scholar
  13. 13.
    Grimley PM and Aszalos A, Early membrane depolarization by alpha interferon: Biologic correlation with antiproliferative signal. Biochem. Biophys. Res. Commun. 146: 300–306, 1987.PubMedCrossRefGoogle Scholar
  14. 14.
    Gm Y, Weaver JL, Pine PS, Zoon KC and Aszalos A, Aurintricarboxylic acid, the anti-AIDS compound, prevents the binding of interferon-alpha to its receptor. Biochem. Biophys. Res. Commun. 172: 1298–1303, 1990.CrossRefGoogle Scholar
  15. 15.
    McDougal JS, Nicholson JKA, Cross GD, Cort SP, Kennedy MS and Mawle AC, Binding of the human retrovirus HTLV-III/LAC/ARV/HIV the CD4 (T4) molecule; conformation dependence, epitope mapping, antibody inhibition, and potential for idiotype mimicry. J. Immunol. 137: 2937–2944, 1986.PubMedGoogle Scholar
  16. 16.
    Chang RS, Tabba HD, He Y and Smith KM, Dextran sulfate as an inhibitor against the human immunodeficiency virus (42811). Proc. Soc. Exp. Biol. Med. 189: 304–309, 1988.PubMedGoogle Scholar
  17. 17.
    Thiele B, Braig HR, Ehm I, Kunze R and Ruf B, Influence of sulfated carbohydrates on the accessibility of CD4 and other CD molecules on the cell surface and implications for human immunodeficiency virus infection. Eur. J. Immunol. 19: 1161–1164, 1989.PubMedCrossRefGoogle Scholar
  18. 18.
    Cushman M, Wang P, Chang SH, Wild C, De Clercq E, Schols D, Goldman ME and Bowen JA, Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. J. Med. Chem. 34: 329–337, 1991.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. Aszalos
    • 1
  • P. S. Pine
    • 1
  • J. Weaver
    • 1
  1. 1.Food and Drug AdministrationUSA

Personalised recommendations